Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old (IFM-CRd)

NCT02405364 Phase 2 COMPLETED

The purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.

Details

Lead sponsor	University Hospital, Toulouse
Phase	Phase 2
Status	COMPLETED
Enrolment	46
Start date	2014-02
Completion	2019-11-25

Conditions

• Multiple Myeloma

Interventions

• Carfilzomib/Lenalidomide/Dexamethasone

Primary outcomes

• rate of stringent complete response — 12 months
  completion of consolidation

Countries

France